Skip to main content
Clinical Trials/NCT00897650
NCT00897650
Completed
Not Applicable

Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy

Vanderbilt-Ingram Cancer Center1 site in 1 country204 target enrollmentDecember 2005
ConditionsLung Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lung Cancer
Sponsor
Vanderbilt-Ingram Cancer Center
Enrollment
204
Locations
1
Primary Endpoint
DNA, RNA, and Protein expression patterns and mutational analysis
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

RATIONALE: Studying samples of tumor tissue and blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in genetic material (DNA and RNA) and may also identify protein expression patterns related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study evaluates changes in DNA, RNA, and proteins with the goal of predicting response to treatment in patients with lung cancer.

Detailed Description

OBJECTIVES: * To determine protein and/or RNA expression patterns capable of predicting tumor response to therapy in tumor tissue samples from patients with lung cancer or suspected of having lung cancer. * To characterize the genes and proteins found to be predictive of response in order to help elucidate the molecular biology underlying cancer chemosensitivity. * To evaluate DNA mutations found within the lung cancer sample which may be predictive of response or resistance to certain therapeutic agents. OUTLINE: Patients undergo collection of tumor tissue by percutaneous fine needle aspiration, core biopsy, thoracentesis, or during any medically indicated procedure involving removal of lung cancer tissue. Tissue samples are analyzed by a variety of techniques, including DNA sequencing, RNA sequencing and expression levels, protein assessment \[by immunohistochemistry, western blot, Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-MS\]). The goal of these studies is to identify of gene mutations, gene expression levels, and proteins predictive of treatment response. Blood samples are also collected to obtain normal DNA for analysis. After completion of study, patients will be followed until their death.

Registry
clinicaltrials.gov
Start Date
December 2005
End Date
July 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Christine Lovly, MD, PhD

Assistant Professor of Medicine and Cancer Biology

Vanderbilt-Ingram Cancer Center

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

DNA, RNA, and Protein expression patterns and mutational analysis

Time Frame: After lung tumor tissue and blood collection.

DNA, RNA, and Protein expression patterns and mutation status in lung tumor tissue that are capable of predicting tumor response to therapy

Secondary Outcomes

  • Characterization of genes and proteins predictive of response to therapy(After lung tumor tissue and blood collection)

Study Sites (1)

Loading locations...

Similar Trials